SynergenX Network Clinics Expand Peptide Therapy Options with BPC-157 and CJC-1295 + Ipamorelin

New treatments available October 6, 2025 at SynergenX, Low T Center, and HerKare

HOUSTON--(BUSINESS WIRE)--SynergenX, veteran-owned leader in personalized hormone and wellness medicine, is expanding its peptide therapy program with the addition of BPC-157 and CJC-1295 + Ipamorelin, two popular new peptide therapies that allow patients to pursue natural, rejuvenating option for health optimization, alone or in addition to hormone and weight-loss therapies. Beginning October 6, 2025, patients across SynergenX, Low T Center, and HerKare locations will have access to these advanced medical treatments, which build on the clinics’ existing use of peptide therapies such as Sermorelin.

“Peptides are a natural extension of the work we already do in hormone and wellness medicine,” said Wayne Wilson, Founder and CEO of SynergenX. “By expanding our peptide therapies we’re giving patients cutting-edge resources to recover, restore, and thrive so they can achieve s higher quality of life.”

BPC-157: The Body Protection Peptide

BPC-157 is known for accelerating recovery in muscles, tendons, and ligaments, making it ideal for patients healing from injuries or surgery, managing chronic joint pain, or seeking relief from inflammation. Benefits may include faster recovery, reduced pain, and possible gastrointestinal protection.

CJC-1295 + Ipamorelin: The Vitality Amplifier

This peptide combination stimulates natural growth hormone release to support energy, recovery, and healthy aging. Potential benefits include improved muscle repair, enhanced metabolism, body composition support, and regenerative effects without direct hormone replacement.

Why Choose SynergenX Network Clinics?

SynergenX has built its reputation on patient-focused care. Every peptide therapy program is:

• Supervised by licensed providers with expertise in regenerative and hormone medicine
• Personalized through lab work, diagnostics, and health goals
• Supported by ongoing follow-up to ensure safety and sustainable results

The addition of these new peptide therapies gives patients more options than ever, and further cements SynergenX’s place as a leader in the health and wellness industry. Appointments for BPC-157 and CJC-1295 + Ipamorelin begin October 6, 2025.

About SynergenX

SynergenX is a veteran-owned, patient-focused provider specializing in hormone therapy and wellness care for men and women. With multiple nationwide locations, the SynergenX network helps patients restore balance, improve vitality, and achieve a better quality of life.